Press Releases April 7, 2026 08:00 PM

electroCore to Participate in the 25th Annual Needham Virtual Healthcare Conference

electroCore to Present at the 25th Annual Needham Virtual Healthcare Conference

By Avery Klein ECOR
electroCore to Participate in the 25th Annual Needham Virtual Healthcare Conference
ECOR

electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, announced its participation in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. Interim President and CFO Joshua Lev will present and engage in investor meetings to discuss the company's innovative non-invasive bioelectronic technologies and product portfolio.

Key Points

  • electroCore specializes in non-invasive neuromodulation technology with products like gammaCore and Quell for chronic pain.
  • The company is leveraging virtual platforms to engage with investors and increase visibility in the healthcare sector.
  • Participation in a prominent healthcare conference may enhance investor awareness and market positioning in bioelectronic medicine.

ROCKAWAY, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place virtually on April 15, 2026.

Joshua Lev, Interim President and Chief Financial Officer, will host a company presentation at 2:15 pm ET and participate in one-on-one meetings throughout the day.

DATE: April 15, 2026
TIME: 2:15 pm ET

Investors attending the conference who are interested in scheduling a meeting with management can do so by contacting their Needham representative, or by emailing ECOR Investor Relations at [email protected].

About electroCore, Inc.

electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.

For more information, visit www.electrocore.com.

Contact:
ECOR Investor Relations
(973) 302-9253
[email protected]


Risks

  • The press release does not disclose new clinical data or product launches, limiting near-term growth catalysts.
  • Market reception depends on continued adoption and reimbursement of bioelectronic therapies, which can be uncertain.
  • Competition in the medical device and bioelectronic sector may impact electroCore's market share and revenue growth.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026